Hemab
Christine Borowski, PhD, is a Vice President at Access Biotechnology. Before joining Access, she worked on therapeutics company creation at Apple Tree Partners. Prior to becoming an investor, Christine was an editor at several high-impact scientific journals, most recently Chief Editor of Nature Medicine. She earned a Ph.D. in Immunology at Harvard University and did her postdoctoral work in immunology at the University of Chicago.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Hemab
Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.